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Assessment of low-grade glioma treatment response remains as much of a challenge as the treatment itself. Proton magnetic
resonance spectroscopy (
1H-MRS) and imaging were incorporated into a study of patients receiving temozolomide therapy for low-
grade glioma in order to evaluate and monitor tumour metabolite and volume changes during treatment. Patients (n¼12) received
oral temozolomide (200mgm
 2day
 1) over 5 days on a 28-day cycle for 12 cycles. Response assessment included baseline and
three-monthly magnetic resonance imaging studies (pretreatment, 3, 6, 9 and 12 months) assessing the tumour size. Short (TE (echo
time)¼20ms) and long (TE¼135ms) echo time single voxel spectroscopy was performed in parallel to determine metabolite
profiles. The mean tumour volume change at the end of treatment was  33% (s.d.¼20). The dominant metabolite in long echo time
spectra was choline. At 12 months, a significant reduction in the mean choline signal was observed compared with the pretreatment
(P¼0.035) and 3-month scan (P¼0.021). The reduction in the tumour choline/water signal paralleled tumour volume change and
may reflect the therapeutic effect of temozolomide.
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Low-grade gliomas (World Health Organisation (WHO) grade II
astrocytoma, oligodendroglioma and mixed oligoastrocytoma)
tend to be slow-growing tumours (Behin et al, 2003) and there
remains considerable debate about the appropriate first-line
treatment (Stieber, 2001; Rees, 2002). A policy of surveillance is
widely accepted and active treatment in the form of surgery or
radiotherapy is generally offered at the time of tumour progres-
sion. With the recognition of chemoresponsiveness of grade III
anaplastic oligodendroglioma (Cairncross et al, 1994) and a
suggestion of efficacy of chemotherapy in grade II oligodendro-
glioma (Glass et al, 1992; Mason et al, 1996; Peterson et al, 1996),
an increasing number of patients with grade II neuroepithelial
tumours have been treated with chemotherapy. However, this
approach has largely been reserved for patients who failed first-
line treatment with surgery and radiotherapy. Initial reports of the
effectiveness of chemotherapy in grade II glial tumours employed
nitrosoureas usually as the PCV (procarbazine, CCNU (1-(2-
chloroethyl)-3-cyclohexyl-1-nitrosourea), vincristine) regimen
(Glass et al, 1992; Mason et al, 1996; Peterson et al, 1996).
Temozolomide is a well-tolerated oral alkylating agent with
almost complete bioavailability that crosses the intact blood–brain
barrier. It is licensed for the treatment of recurrent malignant
glioma (glioblastoma multiforme and anaplastic astrocytoma)
(Yung et al, 1999, 2000; Brada et al, 2001). The 35% response rate
in WHO grade III astrocytoma (anaplastic astrocytoma) (Yung
et al, 1999) in comparison to 6–8% response rate in grade IV
tumours (glioblastoma multiforme) (Yung et al, 2000; Brada et al,
2001) suggests a possible trend of increasing efficacy in lower
grade tumours previously noted for nitrosourea-containing
chemotherapy (Rajan et al, 1994). On the basis of excellent
tolerance and potential efficacy of temozolomide in lower grade
tumours, we evaluated temozolomide as the primary treatment
following surgery in patients with grade II glial tumours in a single
arm phase II study. The results of the study are the subject of a
separate report (Brada et al, 2003).
Imaging with either MRI or CT remains the mainstay for
radiological response assessment in low-grade glioma management
(Ricci and Dungan, 2001). Serial measurement of either the low-
density regions on CT or those areas of high signal intensity
relative to normal adjacent brain on T2-weighted (T2W) MR
images and FLAIR (FLuid Attenuated Inversion Recovery) are
used to quantify treatment response. Despite advances in imaging,
delineation of low-grade tumours is difficult. These lesions seldom
enhance following administration of paramagnetic contrast agents
due to an intact blood–brain barrier, and the diffusely infiltrative
nature of these tumours makes the assessment of tumour
boundaries difficult.
Proton magnetic resonance spectroscopy (
1H-MRS) is a non-
invasive technique describing aspects of tumour biology that can
be readily incorporated into standard diagnostic MRI protocols
(Smith and Stewart, 2002). The potential diagnostic and prognostic
capabilities of
1H-MRS in brain tumours have received consider-
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lable attention (Tedeschi et al, 1997; Nelson et al, 1999; Poptani
et al, 1999; Preul et al, 2000). It would be reasonable to expect that
morphological and clinical responses are preceded by a change in
the tumour biochemistry. It remains to be answered whether such
changes are detectable by MRS and if so whether they provide
sensitive indices of response and/or prognosis.
The aim of this study therefore was to assess the serial metabolic
changes detectable by
1H-MRS in low-grade glioma patients
receiving single-agent temozolomide therapy.
MATERIALS AND METHODS
Patient selection
In all, 13 patients with histologically verified WHO grade II glioma
(nine astrocytoma, four oligodendroglioma) were recruited. They
had evaluable disease on imaging and no previous antitumour
treatment other than surgery (biopsy or debulking surgery), with
either stable or progressive disease. The median age was 39 years;
seven were men and six were women. Patients with radiological or
histological evidence of transformation to high-grade tumours
were excluded. Patients in need of urgent decompressive surgery
or radiotherapy due to rapidly evolving neurological deficit and
patients who had raised intracranial pressure and were corticos-
teroid dependent were not included. Treatment commenced 1–44
months (median 22 months) after histologically confirmed
diagnosis.
The local Scientific and Ethics Committees approved the study
protocol, and patients were required to sign informed consent
prior to entry into the study.
Treatment
Patients received temozolomide at 200mgm
 2day
 1 for 5
consecutive days on a 28-day cycle and the dose and frequency
were adjusted according to standard toxicity criteria (Brada et al,
1999, 2001; Yung et al, 1999). Patients were intended to receive a
maximum of 12 cycles of temozolomide; treatment was discon-
tinued in the presence of disease progression or due to
unacceptable toxicity.
Magnetic resonance imaging
All MR measurements were performed on a 1.5T. Siemens Vision
(Erlangen, Germany) system using the manufacturer’s circularly
polarised head coil and the same protocol was used for each visit
throughout the trial. The full MRI protocol consisted of standard
diagnostic MRI together with MRS acquisitions. Precontrast, the
images were acquired using: T1-weighted (T1W) coronal (TR
(repetition time)¼570ms, TE (echo time)¼14ms, slice thick-
ness¼8mm), T2W coronal (TR¼4500ms, TE¼99ms, slice
thickness¼8mm) and axial FLAIR (TR¼8000ms, TE¼119ms,
TI (inversion time)¼2400ms, slice thickness¼6mm, slice
separation¼0mm). All patients received bolus administration of
double-dose (0.2mmolkg
 1) Gd-DTPA (gadolinium diethylene-
triamine pentaacetic acid, Schering Healthcare, UK). Postcontrast
T1W coronal scans were acquired with the same sequence
parameters as the precontrast acquisition. The study was
performed within 2 weeks before the start of treatment and three
monthly thereafter during the 12 months of treatment, at 3, 6, 9
and 12 months.
Tumour size was assessed as the region of high signal intensity
on FLAIR images by two observers (LV, CA) in consensus. The
FLAIR sequence was chosen for quantification because it is
standard practice at our institution, and of the sequences available
to us, it is the sequence most sensitive to tumour-induced changes.
The assessment was not blinded. The abnormality was outlined
manually on each two-dimensional slice and the area calculated via
an automated procedure. The volume of the FLAIR abnormality
was calculated by summing all the areas and multiplying by the
thickness of all the involved slices. Standard response criteria were
applied, where partial response is defined as 450% reduction in
size and disease progression is 425% increase in tumour size. For
purposes of this study, a 25–50% reduction in tumour size has
been considered as a minimal response. A change in size between
that of a minimal response and that of disease progression was
classified as stable disease.
Magnetic resonance spectroscopy
All spectra were acquired precontrast, using single voxel STEAM
(Stimulated Echo Acquisition Mode) methodology with a mean
voxel size of 10.9cm
3 (range: 10.6–12.2cm
3). The criteria used by
an experienced radiologist (ADJ) for positioning the spectroscopic
voxel included: (1) voxel placement centrally within the FLAIR-
defined abnormality, including where evident, a distinct mass
lesion (as compared with white matter tract abnormality).
Substantial radiologically defined cystic regions were excluded
from the voxel. (2) Exclusion from the voxel of brain tissue
deemed normal on the FLAIR image. For follow-up spectroscopy,
images detailing the previous voxel position were available to the
radiologist ensuring voxel colocation between studies. Voxel
placement at subsequent examinations was performed by the
same radiologist. Spectra were acquired at long (TE¼135ms) and
short (TE¼20ms) echo times with TR¼2500ms and number of
averages¼64. A water reference spectrum was acquired from the
same voxel with TE¼20ms, TR¼2500ms and number of
averages¼4. Spectral analysis was performed using the VARPRO
(Variable Projection) method (van den Boogaart et al, 1994) with
MRUI (Magnetic Resonance User Interface) software. Both
metabolite and water peaks (from the reference spectrum) were
fitted using Lorentzian line shapes. The metabolite signal areas
were normalised to the relevant water signal area (TE¼20ms). For
choline and creatine quantification, the peak areas of the long echo
time spectra were determined and divided by the short echo time
water spectrum. For N-acetyl aspartate (NAA), the short echo time
spectra were quantified due to the very low signal-to-noise of this
peak at long echo time. The short echo time spectra also served to
detect lipid methyl and methylene signals.
Statistics
Normality within a data set was tested using a Shapiro–Wilk test
and paired groups of data were compared using a paired t-test.
Differences in the mean of the choline/water values were assessed
between pretreatment values and the data at 3, 6, 9 and 12 months.
RESULTS
A summary of data for all patients receiving temozolomide for the
full 12-month course of treatment is given in Table 1.
Clinical summary
Out of 13 patients who started treatment, 12 completed the 12-
month cycle. One patient was removed from the study after 9
months due to deterioration in physical condition and was
radiologically confirmed to have undergone high-grade transfor-
mation. The following results apply to the 12 patients who
completed the full course of treatment.
Imaging analysis
A summary of the imaging data is provided in Table 1. All patients
had an initial reduction in tumour volume as measured at 3 and 6
months. The mean reduction was 23% (range  4% -  47%) at 6
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lmonths and 33% (range þ12% -  52%) at 12 months. Two
patients showed a small increase in tumour size at 12 months. An
example of tumour volume reduction is shown in Figure 1.
Therefore 12 months following the start of treatment, two patients
had stable disease, eight had a minimal response and two had a
partial response.
Spectroscopy
Spectroscopy was successfully completed on all patients at
3 months, 10 out of 12 patients at 6 months, nine out of
12 patients at 9 months and 11 out of 12 patients at 12 months.
Spectroscopy was not performed on six occasions due to technical
problems or the patients being unable to tolerate the full MR
protocol.
An example series of long echo time spectra (TE¼135ms)
obtained during temozolomide treatment is shown in Figure 2 (left
of figure). These spectra are from patient #5 whose tumour volume
had reduced by 40% at 12 months. The MRS voxel positions are
shown in the FLAIR and T2W images in Figure 1. The principal
1H-MRS features of a low-grade glioma are illustrated in the
pretreatment spectrum in Figure 2 (A, left of figure): a dominant
Table 1 Summary of imaging and spectroscopy results for the 12 patients completing 12 months of treatment
Magnetic resonance spectroscopy
Patient
Magnetic resonance imaging
Volume change
(12months) (%)
Pretreatment Post-treatment
Choline/water
( 10
 5)
(TE¼135s)
NAA/water
( 10
 5)
(TE¼20ms)
% choline at
12 months
(TE¼135ms)
% NAA at
12 months
(TE¼20ms)
1 +12 12 19  16  14
2  34 15 19  100  100
3  32 27 0  25 No NAA
4  39 13 0 —
a —
a
5  40 27 6  35 +160
6  38 26 0  60 No NAA
7  51 22 19 +14  25
8  47 17 22  42  40
9  52 26 12 +24 +220
10 +3 21 0 +10 No NAA
11  44 17 22  50 +328
12  32 22 0  51 No NAA
Mean (s.d.)  33 (20) 20 (6) 10 (10)  30 (37) 76 (160)
aThe instances where the full spectroscopy examination could not be completed are indicated. The volume column refers to the % change as determined by FLAIR MRI. The
spectroscopic quantification of choline is that derived from the long echo (TE¼135ms) time acquisitions. The quantification of NAA is derived from the short echo time spectra
(TE¼20ms). NAA¼N-acetyl aspartate. TE¼Echo time.
AB D C E
Figure 1 A series of images from patient #5 demonstrating the reduction in tumour volume apparent on FLAIR (top) and T2W-FSE (bottom) images.
Images displayed are from (A) pretreatment and post-treatment at (B) 3 months, (C) 6 months, (D) 9 months and (E) 12 months. Note the visible
reduction in abnormal signal intensity on the FLAIR image during the course of the patient’s treatment with temozolomide. A postsurgical cavity (seen as low
signal in the axial images) is situated immediately posterior to the abnormal high signal intensity. (The cross hairs in each image indicate the magnetic
isocentre. Where the voxel is not represented as a single square was due to the obliquity of the underlying reference images).
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lcholine signal, low-intensity creatine and NAA and no quantifiable
lipid or lactate.
Short echo time spectra (TE¼20ms) from the same patient are
also shown in Figure 2 (right of figure). The signal-to-noise ratio is
considerably greater than at longer echo time for the same number
of acquisitions, indicating short metabolite T2 values. The lipid
methyl (0.9ppm) and methylene (1.2ppm) peaks not visible at
TE¼135ms display high signal intensity.
The choline data displayed in Table 1 are those obtained from
the analysis of the long echo time (TE¼135ms) spectra. For
quantitative temporal analysis, the only consistently fitted peak in
all patients was choline (with the exception of patient #4). The
intensities of NAA and creatine were commonly too low for
quantification at long echo time.
At 6 months, seven out of 10 patients demonstrated a reduction
in choline signal. At 12 months, eight out of 11 patients showed
choline reduction. One patient (#2) demonstrated a complete loss
of choline signal at 6 months that persisted in subsequent scans.
N-acetyl aspartate was quantifiable in seven out of 12 patients in
the short echo time pretreatment spectra. Three patients demon-
strated large increases in NAA concentration (þ160%, þ220%
and þ328%) at 12 months. Pretreatment lipid was only observed
in three of the 12 patients in the short-echo time spectra (patients
#2, #5 and #9).
Figure 3 shows the mean percentage of choline and FLAIR
tumour volume from the 12 patients. For the purpose of
illustration, all post-treatment values have been normalised to
the pretreatment choline and volume data, respectively.
Statistics
The Shapiro–Wilk test indicated that there was no statistically
significant evidence to assume that the choline/water data were
not normally distributed at each of the experimental time
points, and therefore paired t-tests were performed between
paired groups of data. There was a statistically significant
difference between the pretreatment and the 12-month choline/
water data (P¼0.035) and the 3- and 12-month data (P¼0.021).
No difference was detected between the pretreatment and 3-month
data (P¼0.73). No statistically significant differences were
detected between the other groups of data. Statistical significance
was taken at the 95% level.
DISCUSSION
Morphological imaging often does not adequately reflect under-
lying tumour biology and is illustrated by low-grade gliomas where
the tumour periphery is often seemingly well circumscribed but
histologically quite the opposite (Behin et al, 2003). There is
therefore a considerable incentive to develop alternative measures
of therapeutic response in humans. The results of this study
suggest that therapeutically induced metabolic changes are
clinically detectable using
1H-MRS.
Metabolic changes
Choline The decrease in tumour volume with temozolomide
therapy was closely matched by a decrease in the choline/water
ratio during treatment. The potential biological and clinical
significance of this observation is reinforced by the statistically
significant higher level of choline/water pretreatment and at 3
months as compared with the end treatment values.
It is recognised that MRS-determined choline reflects membrane
synthesis (Tedeschi et al, 1997). Furthermore, the choline
resonance has been correlated with cell density and with indices
of cellular proliferation (Miller et al, 1996). The detected decrease
in choline could be a consequence of the therapeutic effect
of temozolomide and subsequent neoplastic cell death. An
increase in the choline/water suggests an increase in membrane
Figure 2 Long echo time (TE¼135ms, left of figure) and short echo
time (TE¼20ms, right of figure) STEAM spectra obtained from patient #5
during temozolomide treatment: (A) pretreatment, (B) at 3 months, (C)a t
6 months and (D) 9 months. Within both series a progressive decrease in
the choline/creatine ratio is observed, suggesting a reduced membrane
metabolism and diminishing cellular density. Also note the increasing
conspicuity of the NAA peak. N-acetyl aspartate is a specific neuronal
marker and may reflect the regression of tumoral tissue and repopulation of
normal brain matter.
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Figure 3 Mean choline and mean volume expressed as a percentage for
all 12 patients completing the 12 months of treatment. The % choline is
calculated by normalising the TE¼135ms signal to water. For each patient
all post-treatment values were normalised to the pretreatment volume and
choline data. The error bars represent the s.e. associated with the mean.
Note the almost parallel trend in the reduction of tumour choline and
volume.
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lmetabolism and cell density, suggesting an absence or loss of
therapeutic response. In high-grade glioma, choline signals are
predominantly elevated at the tumour periphery where there
is enhanced cellular proliferation supported by an adequate
blood supply. In the core of a high-grade tumour, however,
there is a low choline signal as the viable cell count is reduced
due to necrosis. Necrosis is not a feature of low-grade glioma
and therefore, in the absence of high-grade transformation
treatment-mediated cell death is a more likely cause of choline
reduction. A reduction in choline signal intensity within the
context of this study may be a metabolic indicator of response to
temozolomide therapy.
Furthermore, a reduction in the tumour choline does not
follow the previously reported metabolic evolution of this
tumour type. In a study (Tedeschi et al, 1997), serial measure-
ments of the choline signal were carried out in patients with
low-grade astrocytoma (WHO grade II), low-grade oligodendro-
glioma (WHO grade II), anaplastic astrocytomas (WHO grade III)
and high-grade astrocytomas (WHO grade IV). This study
categorised patients radiologically into stable or progressive
disease. Patients with stable disease showed tumour choline signal
changes between  33 and þ28% with a mean of 0.4%. Those
individuals with progressive disease demonstrated choline
signal changes in the range þ46 to þ104% with a mean of
55.6%. In this current study, the reduction in choline demonstrates
changes opposite to those associated with progressive disease
and remains distinct from the metabolically static situation of
stable disease.
N-acetyl aspartate N-acetyl aspartate was visible in seven
out of 12 patients in the short echo time pretreatment spectra.
Three patients demonstrated large increases in NAA concentra-
tion (160%, 220% and 328%], all of whom demonstrated a
response: two minimal and one partial. The images from one of
these patients (160% NAA) are used as an example in Figure 1. It
can be seen from the overlaid MRS voxel that during treat-
ment the amount of radiologically normal tissue within the
voxel increases as the tumour reduces in size. This is supported
by the increase in NAA with time as the normal tissue returns
to the site originally infiltrated by tumour tissue. This demon-
strates a metabolic feature that could be explained by the
diffusely infiltrative nature of low-grade glioma, resulting in
invasion rather than destruction of surrounding brain tissue.
If tumour cells are therapeutically killed, the normal tissue
may return into the space once occupied by tumour. As
NAA is a sensitive indicator of neuronal density (Nadler and
Cooper, 1972), the increase in NAA supports the proposed
mechanism. Sensitivity to this process will, however, be
technology dependent. If the voxel is sited in the centre of a large
tumour then it may require a large change in tumour volume to
detect an alteration in NAA. This may reflect why NAA did not
increase in some tumours that demonstrated a substantial
reduction in tumour volume.
It is also possible that signal processing issues may
have influenced NAA quantification. The complex of peaks
around 2.0ppm often poses difficulties in automated fitting
routines. The inevitable minor variation in voxel positioning
in serial examinations could have resulted in some variation
in the degree to which normal brain NAA influences the
spectrum. A spectroscopic imaging approach would address
these issues.
Lipid No methyl or methylene lipid signals were observed
in the long echo time spectra, before or during treatment.
Since MRS- visible mobile lipids are associated with necrosis
in brain tumours (Barba et al, 1999) this observation is
consistent, acknowledging the limits in sensitivity of MR with
the histology of low-grade tumours. At short echo time, however,
low levels of lipid methylene and methyl signals were detected
in three out of 12 patients. These three patients demonstrated
improvement in clinical symptoms and MRI volume reduc-
tion. The lipid signal in Figure 2 (right of figure) reduces
during treatment. However, as only three patients displayed
quantifiable lipids, it was inappropriate to calculate the
statistical significance of these changes with respect to treatment
response. As the majority of individuals showing clinical
improvement did not express any significant spectroscopically
detectable lipid resonance, its presence does not appear to be
prognostic.
Other metabolites Metabolites other than choline, NAA or lipid
were generally of too low a concentration to be measured in a
serial manner. In those patients in whom creatine could be
measured in sufficient concentration, the creatine/water signal
showed no significant change during treatment.
Methodologically, the application of a single voxel approach to
studying these tumours may cause ambiguity. The heterogeneity of
metabolic response cannot be assessed with a single voxel
approach. Also, it is not readily feasible (with NAA, for example)
to discriminate between tumour cells dying and normal tissues
returning within the spectroscopic voxel. The result is likely to be a
combination of both phenomena, particularly with small tumours
where post-treatment normal tissue can be seen radiologically
within the voxel. However, many of these low-grade gliomas were
sufficiently large to give confidence that radiologically defined
normal tissue was not within the voxel even after tumour
shrinkage. Another important methodological issue is the study-
to-study placement of the voxel. Some of the changes between the
spectra could be due to study-to-study misregistration. However, it
is unlikely that misregistration will result in signal change in a
particular direction and so the introduced error is likely to be an
overall uncertainty rather than a bias.
CONCLUSION
Our results indicate that changes in the
1H-MRS profile of low-
grade glioma that parallel volume changes in the tumour can be
detected during the course of temozolomide treatment. Further-
more, our study indicates that metabolic changes do not
apparently precede changes in tumour volume within the limits
of the measurement sensitivity and temporal sampling. Early
metabolic response may be a heterogeneous phenomenon below
the limits of sensitivity of the current technique. Methodological
improvements, including higher field strength and a spectroscopic
imaging approach are likely to enhance the value of investigating
associations between metabolic response and the morphological
consequence of chemotherapy.
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